secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2026-05-14T00:35:37+00:00
Accession:  0001213900-26-056109
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix reports Q1 2026 progress: two Proclarix publications, PRIME study with Labcorp, European expansion
--------------------------------------------------------------------------------

- Two peer-reviewed papers published: Schiess et al. in BMC Cancer (371 men) and Athanasiou et al. in Cancers (132 men) reinforce Proclarix performance in reducing unnecessary biopsies.
- PRIME multi-center clinical study initiated with Labcorp; first participants enrolled, targeting up to 500 men for U.S. validation.
- European commercial expansion: ~100 Proclarix tests performed in UK screening initiative in Q1 2026; collaboration partner identified in Turkey.
- Proclarix is a CE-IVD certified blood test for identifying clinically significant prostate cancer, designed to reduce overdiagnosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390026056109/0001213900-26-056109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390026056109/ea0290739-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-056109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer